Astellas goes hostile, offering a 40% premium to buy OSI Pharma for $3.5 billion

1 March 2010

Despite previous rejections of its advances, Japanese drug major Astellas Pharma this morning said it plans to acquire USA-based OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of some $3.5 billion on a fully diluted basis, representing a significant premium of over 40% on the closing price of OSI's common stock of $37.02 per share on February 26, 2010, a 53% premium to its three-month average of $34.01 per share, and a 31% premium to its 52-week high of $39.66 per share. Astellas' hostile tender offer to shareholders, which is not subject to any financing conditions, will commence tomorrow, the firm stated.

The acquisition of OSI - a biotechnology company primarily focused on the discovery, development and commercialization of molecular-targeted therapies addressing medical needs in cancer, diabetes and obesity - would support Astellas' growth strategy of becoming a global category leader in oncology. OSI would also augment Astellas' strong existing franchises in urology and immunology, it was noted.

Access to Tarceva

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK